Nephrogen Email Format
Biotechnology ResearchNew York, United States2-10 Employees
Nephrogen is a biotechnology research company based in New York City, founded as a Stanford biotech spin-out focused on developing curative genetic medicines for kidney and pancreatic diseases. The organization aims to improve outcomes for kidney disease patients, a condition affecting a significant portion of Americans, by engineering gene delivery vehicles that are safer, more efficient, and less expensive to reach the kidney and pancreas. Its work sits at the intersection of artificial intelligence and high-throughput screening within the broader biotech landscape, with the goal of advancing gene-based therapies where few options exist today. Nephrogen operates with a small team and has placed its activities in the United States, leveraging proximity to major biotech ecosystems to pursue its research objectives. A recent note indicates participation in TechCrunch Disrupt 2025, reflecting engagement with the broader technology and biotech community.